AVIR vs RDVT

Red Violet, Inc.

(RDVT) offers the better valuation at 53. 9x trailing P/E (36. 5x forward), making it the more compelling value choice. Analysts rate Red Violet, Inc. (RDVT) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Red Violet, Inc.

(RDVT) delivered a total return of +155. 9%, compared to -74. 0% for Atea Pharmaceuticals, Inc. (AVIR). Over 10 years, the gap is even starker: RDVT returned +6. 4% versus AVIR's -81. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Atea Pharmaceuticals, Inc.

(AVIR) is the lower-risk stock at 1. 05β versus Red Violet, Inc. 's 1. 17β — meaning RDVT is approximately 11% more volatile than AVIR relative to the S&P 500. On balance sheet safety, Atea Pharmaceuticals, Inc. (AVIR) carries a lower debt/equity ratio of 0% versus 3% for Red Violet, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Red Violet, Inc.

grew EPS 82. 0% year-over-year, compared to 3. 0% for Atea Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Red Violet, Inc.

(RDVT) is the more profitable company, earning 14. 6% net margin versus 0. 0% for Atea Pharmaceuticals, Inc. — meaning it keeps 14. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RDVT leads at 14. 6% versus 0. 0% for AVIR. At the gross margin level — before operating expenses — RDVT leads at 83. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for AVIR: 80.

5% to $10. 00.

In this comparison, RDVT (0.

6% yield) pays a dividend. AVIR does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Red Violet, Inc.

(RDVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 17), 0. 6% yield). Both have compounded well over 10 years (RDVT: +6. 4%, AVIR: -81. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (AVIR (Healthcare) and RDVT (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: AVIR is a small-cap quality compounder stock; RDVT is a small-cap high-growth stock. RDVT pays a dividend while AVIR does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.